Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trospium chloride inhalation
- Development stage
- Discontinued
- Lead developer
- Alkermes
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
ALKS 27 is an inhaled formulation of trospium chloride developed for the treatment of chronic obstructive pulmonary disease (COPD). Trospium chloride is a muscarinic receptor antagonist that works by relaxing smooth muscle tissue in the airways, thereby improving airflow and lung function. The drug was designed using Alkermes' proprietary AIR pulmonary delivery technology to provide rapid onset and prolonged bronchodilation with once-daily administration. Clinical studies demonstrated significant improvements in lung function compared to placebo and a favorable safety profile over a wide dose range[1][2][3][4][5].
- Other names
- ALKS 27ALKS27ALKS-27TrIPtrospium chloride inhalation
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)CHRM5 (M5)CHRM2 (M2)CHRM4 (M4)
Beyond the preview
Go deeper on trospium chloride inhalation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trospium chloride inhalation.